Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae

APMIS

Volumn 119, Issue 12, 2011, Pages 853-863

  Titelman, Emilia ^a   Iversen, Aina ^a   Kahlmeter, Gunnar ^b,c   Giske, Christian G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cefotaxime; Ceftazidime; ESBL; Interpretive reading; SHV

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; MECILLINAM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TEMOCILLIN; TIGECYCLINE; TRIMETHOPRIM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; DISK DIFFUSION; DNA SEQUENCE; EPSILOMETER TEST; ESCHERICHIA COLI; GENOTYPE; INTERMETHOD COMPARISON; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; INJECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 81355149261     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02766.x     Document Type: Article

References (35)

1. Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010;70:313-33.
2. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-74.
3. Cars O, Olsson-Liljequist B, Lundh K. Short summary of Swedres 2005, a report on Swedish antibiotic utilisation and resistance. Euro Surveill 2007;12:225.
4. Naseer U, Natas OB, Haldorsen BC, Bue B, Grundt H, Walsh TR, et al. Nosocomial outbreak of CTX-M-15-producing E. coli in Norway. APMIS 2007;115:120-6.
5. Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 2008;46:707-12.
6. Fang H, Lundberg C, Olsson-Liljequist B, Hedin G, Lindback E, Rosenberg A, et al. Molecular epidemiological analysis of Escherichia coli isolates producing extended-spectrum beta-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden. J Clin Microbiol 2004;42:5917-20.
7. Lytsy B, Sandegren L, Tano E, Torell E, Andersson DI, Melhus A. The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant Klebsiella pneumoniae producing CTX-M-15. APMIS 2008;116:302-8.
8. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-9.
9. Elliott E, Brink AJ, van Greune J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006;42:e95-8.
10. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008;14(Suppl 1):181-4.
11. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-66.
12. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect 2007;54:463-8.
13. Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006;57:1012-4.
14. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008;14(Suppl 1):198-202.
15. Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897-902.
16. Tasbakan HP, SO, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum β -lactamase producing E. coli related lower urinary tract infection. 48th Annual ICAAC/IDSA 46th Annual Meeting, October 25-28, 2008, Washington, 2008.
17. Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006;57:367-8.
18. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. 2011. (accessed 14 February 2011).
19. EUCAST. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect 2000;6:509-15.
20. De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008;61:382-8.
21. EUCAST. Disk diffusion test. 2011. (accessed 16 February 2011).
22. Sundsfjord A, Simonsen GS, Haldorsen BC, Haaheim H, Hjelmevoll SO, Littauer P, et al. Genetic methods for detection of antimicrobial resistance. APMIS 2004;112:815-37.
23. Jouini A, Vinue L, Slama KB, Saenz Y, Klibi N, Hammami S, et al. Characterization of CTX-M and SHV extended-spectrum beta-lactamases and associated resistance genes in Escherichia coli strains of food samples in Tunisia. J Antimicrob Chemother 2007;60:1137-41.
24. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-7.
25. BLAST. Basic Local Alignment Search Tool. 2008. (accessed 19 December 2008).
26. PulseNet [database on the Internet] 2008. (accessed 17 December 2008).
27. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.
28. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009;64:274-7.
29. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Canica MM, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008;61:273-81.
30. Brolund A, Haeggman S, Edquist PJ, Gezelius L, Olsson-Liljequist B, Wisell KT, et al. The DiversiLab system versus pulsed-field gel electrophoresis: characterisation of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Microbiol Methods 2010;83:224-30.
31. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints. Clin Microbiol Infect 2008;14(Suppl 1):169-74.
32. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. M100-S20. 2010. Clinical and Laboratory Standard Institute, Wayne, PA.
33. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
34. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, et al. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007;45:199-205.
35. EUCAST. Zone diameter distributions. (accessed 14 February 2011).